Pyrantel

Mechanism of action at the cellular level

The action of pyrantel is directed exclusively at the neuromuscular apparatus of the parasites. The main pharmacodynamic effect consists in the development of a persistent blockade of cholinergic neuromuscular transmission. Normally, the transmission of nerve impulses ensures the contraction of the helminth's muscle fibers, allowing it to move actively and hold its position in the digestive tract.

Upon exposure to the drug, this process is interrupted, which inevitably leads to total paralysis of the helminth musculature. Immobilized parasites lose the ability to resist natural peristalsis and are passively eliminated from the intestine.

Important for differential diagnosis: unlike other groups of anthelmintics, this substance does not cause a violation of cell membrane permeability, does not lead to the inhibition of microtubule synthesis, and does not carry out GABAergic transmission blockade.

Pharmacokinetic parameters

The drug's pharmacokinetics are ideally suited for targeted treatment of intestinal infestations. After oral administration, the active substance is practically not absorbed in the gastrointestinal tract.

This means that the drug does not enter the systemic circulation in clinically significant concentrations, but acts directly at the site of parasite habitation—in the intestinal lumen. Having passed through the entire digestive tract, the medicinal product is excreted from the body unchanged. This exact pharmacokinetic profile explains the minimal metabolic load on the patient's body.

Clinical use and spectrum of activity

The spectrum of anthelmintic action covers a number of the most common intestinal infestations. In clinical practice, the drug is prescribed upon confirmation of the following diagnoses:

• Ascariasis;
• Enterobiasis;
• Ancylostomiasis;
• Necatoriasis;
• Trichuriasis.

The main clinical feature of this medicinal product is that the drug has low toxicity. Due to the absence of systemic absorption, it is officially approved for use in the most vulnerable categories of patients—children and pregnant women.

Adverse reactions and contraindications

Although the drug is considered highly safe, its administration may be accompanied by a number of side effects.

On the part of the central nervous system, patients may experience headache as well as drowsiness. It is important to remember this nuance for exams: the drug causes specifically drowsiness, and not insomnia. On the part of the gastrointestinal tract, where the unabsorbed substance is concentrated, nausea and diarrhea may develop. Dermatological reactions may manifest as skin rashes. At the same time, such severe systemic conditions as alopecia or neutropenia are completely excluded from the spectrum of its side effects.

Strict contraindications include:

1. Individual hypersensitivity to the components;
2. Liver failure (despite the fact that the drug is excreted predominantly unchanged, severe liver pathologies remain a strict restriction).

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Comparative characteristics of the mechanisms of action of anthelmintic agents (cholinergic receptor blockade vs. microtubule inhibition)
• Features of the pharmacokinetics of drugs that are not absorbed in the gastrointestinal tract
• Life cycles of the causative agents of ascariasis and enterobiasis
• Safety profile of anthelmintic drugs during pregnancy
• Differential diagnosis of central nervous system side effects when taking antiparasitic agents

Other topics in the "Drugs for protozoan infections" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.